Tommaso Lo Barco

Tommaso Lo Barco

Auto-generated profile, based on publicly available information

Tommaso Lo Barco

Epilepsy Center, C. Poma Hospital, Mantua, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Clinical Neurophysiology
Verified
Journal Article
Closed access
TBTommaso Lo Barco
Tommaso Lo Barco
AKAnna Kaminska
Anna Kaminska
RSRoberta Solazzi
Roberta Solazzi
CCClaude Cancés
Claude Cancés
GBGiulia Barcia
Giulia Barcia
RNRima Nabbout
Rima Nabbout

1 February 2022 in Epilepsy & Behavior
Verified
Journal Article
Closed access
TBTommaso Lo Barco
Tommaso Lo Barco
LGLuciana De Gaetano
Luciana De Gaetano
ESElisabetta Santangelo
Elisabetta Santangelo
TBTonino Bravi
Tonino Bravi
JPJacopo Proietti
Jacopo Proietti
FDFrancesca Darra
Francesca Darra

20 December 2023 in Epilepsia
Verified
Journal Article
Open access
MKMathieu Kuchenbuch
Mathieu Kuchenbuch
TBTommaso Lo Barco
Tommaso Lo Barco
NCNicole Chemaly
Nicole Chemaly
CCCatherine Chiron
Catherine Chiron
RNRima Nabbout
Rima Nabbout
Objective: This study was undertaken to evaluate our treatment algorithm for infantile epileptic spasms syndrome (IESS) used between 2000 and 2018. We initiated vigabatrin (VGB), and steroids were added if the electroclinical response (spasms and electroencephalogram [EEG]) to VGB was not obtained or incomplete.Methods: Individuals with IESS treated with VGB were recruited from our hospital clinical data warehouse based on electronic health records (EHRs) generated since 2009 and containing relevant keywords. We confirmed the diagnosis of IESS. Clinical, EEG, imaging, and biological data were extracted from the EHRs. We analyzed factors associated with short‐term response, time to response, relapse, time to relapse of spasms, and the presence of spasms at last follow‐up.Results: We collected data from 198 individuals (female: 46.5%, IESS onset: 6 [4.5–10.3] months, follow‐up: 4.6 [2.5–7.6] years, median [Q1–Q3]) including 129 (65.2%) with identifiable etiology. VGB was started 17 (5–57.5) days after IESS diagnosis. A total of 113 individuals were responders (57.1% of the cohort), 64 with VGB alone and 38 with VGB further combined with steroids (56.6% and 33.6% of responders, respectively). Among responders, 33 (29%) experienced relapses of spasms, mostly those with later onset of spasms (p = .002) and those who received VGB for <24 months after spasms cessation compared to a longer duration on VGB (45% vs. 12.8%, p = .003). At follow‐up, 92 individuals were seizure‐free (46.5% of the whole cohort), including 26 free of therapy (13.1%). One hundred twelve individuals (56.6%) were still receiving VGB, with a duration of 3.2 (1.75–5.7) years.Significance: Our sequential protocol introducing VGB then adding steroids is an effective alternative to a combined VGB–steroids approach in IESS. It avoids steroid‐related adverse events, as well as those from VGB–steroid combination. According to our data, a period of 7 days seems sufficient to assess VGB response and enables the addition of steroids rapidly if needed. Continuing VGB for 2 years may balance the risk of relapse and treatment‐induced adverse events.

7 November 2021 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
NCNicole Chemaly
Nicole Chemaly
MKMathieu Kuchenbuch
Mathieu Kuchenbuch
TTThéo Teng
Théo Teng
EMElodie Marie
Elodie Marie
GDGianluca D'Onofrio
Gianluca D'Onofrio
RNRima Nabbout
Rima Nabbout
We aimed to identify caregivers' opinions on the outcome measures that matter in clinical trials in individuals with Dravet syndrome (DS). We conducted a prospective European multicenter study based on an 11 closed questions survey developed by the French reference center for rare epilepsies and DS patients’ advocacy groups. Items included questions on seizures and daily life outcomes that a clinical trial on a therapy for individuals with DS should target. Statistical analyses were performed to evaluate the impact of the country of residence and of the patients’ age. The survey was answered by 153 caregivers (68%: France, 28%: Germany, and 24%: Italy) off individuals with DS. Individuals with DS included 86 males (mean age of 11.4 [interquartile: 7‐20.4] years). Families ranked as important almost all the items proposed. However, items related to daily life had the highest rank in all three countries compared to items about seizures (P = 0.02). Increase in individuals’ age was associated with a higher age at diagnosis (ρ = 0.26, P = 0.02), and a lower impact of seizure duration (ρ = −0.25, P = 0.005) and on the need of hospital referral (ρ = −0.26, P = 0.005). These data can help tailor patient‐centered outcome measures in future clinical and real‐life trials for DS.

30 March 2023 in Epilepsia Open
Verified
Journal Article
Open access
SBSimona Balestrini
Simona Balestrini
VDViola Doccini
Viola Doccini
SGSabrina Giometto
Sabrina Giometto
ELErsilia Lucenteforte
Ersilia Lucenteforte
SMSalvatore De Masi
Salvatore De Masi
RGRenzo Guerrini
Renzo Guerrini
Objectives: We describe the Residras registry, dedicated to Dravet syndrome (DS) and to other phenotypes related to SCN1A mutations, as a paradigm of registry for rare and complex epilepsies. Our primary objectives are to present the tools and framework of the integrative platform, the main characteristics emerging from the patient cohort included in the registry, with emphasis on demographic, clinical outcome, and mortality.Methods: Standardized data of enrolled pediatric and adult patients were collected in 24 Italian expert centers and regularly updated at least on a yearly basis. Patients were prospectively enrolled, at registry starting, but historical retrospective data were also included.Results: At present, 281 individuals with DS and a confirmed SCN1A mutation are included. Most patients have data available on epilepsy (n = 263) and their overall neurological condition (n = 255), based on at least one follow‐up update. Median age at first clinical assessment was 2 years (IQR 0–9) while at last follow‐up was 11 years (IQR 5–18.5). During the 7‐year activity of the registry, five patients died resulting in a mortality rate of 1.84 per 1000‐person‐years. When analyzing clinical changes over the first 5‐year follow‐up, we observed a significant difference in cognitive function (P < 0.001), an increased prevalence of behavioral disorders including attention deficit (P < 0.001), a significant worsening of language (P = 0.001), and intellectual disability (P < 0.001).Significance: The Residras registry represents a large collection of standardized national data for the DS population. The registry platform relies on a shareable and interoperable framework, which promotes multicenter high‐quality data collection. In the future, such integrated platform may represent an invaluable asset for easing access to cohorts of patients that may benefit from clinical trials with emerging novel therapies, for drug safety monitoring, and for delineating natural history. Its framework makes it improvable based on growing experience with its use and easily adaptable to other rare and complex epilepsy syndromes.

30 December 2023 in Epilepsia
Verified
Journal Article
Open access
TBTommaso Lo Barco
Tommaso Lo Barco
NGNicolas Garcelon
Nicolas Garcelon
ANAntoine Neuraz
Antoine Neuraz
RNRima Nabbout
Rima Nabbout
Objective: The increasing implementation of electronic health records allows the use of advanced text‐mining methods for establishing new patient phenotypes and stratification, and for revealing outcome correlations. In this study, we aimed to explore the electronic narrative clinical reports of a cohort of patients with Dravet syndrome (DS) longitudinally followed at our center, to identify the capacity of this methodology to retrace natural history of DS during the early years.Methods: We used a document‐based clinical data warehouse employing natural language processing to recognize the phenotype concepts in the narrative medical reports. We included patients with DS who have a medical report produced before the age of 2 years and a follow‐up after the age of 3 years (“DS cohort,” 56 individuals). We selected two control populations, a “general control cohort” (275 individuals) and a “neurological control cohort” (281 individuals), with similar characteristics in terms of gender, number of reports, and age at last report. To find concepts specifically associated with DS, we performed a phenome‐wide association study using Cox regression, comparing the reports of the three cohorts. We then performed a qualitative analysis of the surviving concepts based on their median age at first appearance.Results: A total of 76 concepts were prevalent in the reports of children with DS. Concepts appearing during the first 2 years were mostly related with the epilepsy features at the onset of DS (convulsive and prolonged seizures triggered by fever, often requiring in‐hospital care). Subsequently, concepts related to new types of seizures and to drug resistance appeared. A series of non‐seizure‐related concepts emerged after the age of 2–3 years, referring to the nonseizure comorbidities classically associated with DS.Significance: The extraction of clinical terms by narrative reports of children with DS allows outlining the known natural history of this rare disease in early childhood. This original model of “longitudinal phenotyping” could be applied to other rare and very rare conditions with poor natural history description.